The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup ...

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

The report shows a rise in medication use, obesity, and smoking, a decline in cancer screenings, concerns over excessive ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...